NEWS
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially registrational trial aims to enroll about 500 participants with pre-symptomatic AD.
Key points:
JNJ-2056 received FDA Fast Track designation in July 2024
AC Immune has received approximately CHF 425 million in milestone and upfront payments from collaborations
The company has a three-year cash runway
ACI-35.030 targets pathological phosphorylated-Tau protein (pTau)
The trial is the first to test an active immunotherapy in preclinical AD population
Key points:
JNJ-2056 received FDA Fast Track designation in July 2024
AC Immune has received approximately CHF 425 million in milestone and upfront payments from collaborations
The company has a three-year cash runway
ACI-35.030 targets pathological phosphorylated-Tau protein (pTau)
The trial is the first to test an active immunotherapy in preclinical AD population
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2536Followers
107Following
27KVisitors
Follow